CELH
Celsius Holdings, Inc.
CELH has the edge over LRN overall, supported by stronger fundamentals and stronger modeled upside.
LRN
Stride, Inc.
LRN has lower modeled downside risk, despite its lower overall score.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LRN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Strong |
LRN's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
LRN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.6x | $75.29 | — |
| Current | 10x | $75.29 | — |
| Cheap | 14x | $104 | +38% |
| Fair | 18x | $131 | +74% |
| Expensive | 24x | $174 | +131% |
Historical ranges are pointers, not guarantees.
LRN has the edge over CELH in the historical PE scenario, which offers more potential upside but is not a forecast.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
CELH has the edge over LRN on the outlook, with more favorable revenue expectations.
LRN Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect LRN's earnings to grow and its profitability to improve, with its revenue holding steady.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH earned $0.90 per share over the past year, about eight times what it earned the year before.
LRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.88 | +9.6% |
| Q3 2026 | $7.19 | +12% |
| Q2 2026 | $7.14 | +20% |
| Q1 2026 | $6.41 | -0.3% |
| Q4 2025 | $6.50 | +8.2% |
| Q3 2025 | $6.41 | +16% |
| Q2 2025 | $5.95 | +27% |
| Q1 2025 | $6.43 | +51% |
| Q4 2024 | $6.01 | +51% |
LRN has the edge over CELH on earnings, with more consistent year-over-year improvement.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH's revenue has grown year over year for six quarters in a row: $847M last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over LRN on profitability, with a higher operating margin.
LRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $639.4M | +3% |
| Q2 2026 | $636.1M | -2.7% |
| Q1 2026 | $629.9M | +2.7% |
| Q4 2025 | $631.3M | +7.5% |
| Q3 2025 | $620.9M | +13% |
| Q2 2025 | $653.6M | +22% |
| Q1 2025 | $613.4M | +18% |
| Q4 2024 | $587.2M | +16% |
LRN's revenue has held roughly level: $639M last quarter, up 3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +2.1 points |
| Q2 2026 | 17% | +7.9 points |
| Q1 2026 | 20% | -0.8 points |
| Q4 2025 | 23% | +2 points |
| Q3 2025 | 11% | +2.5 points |
| Q2 2025 | 8.7% | -5.1 points |
| Q1 2025 | 21% | +4.4 points |
| Q4 2024 | 21% | +4.6 points |
LRN's operating margin was 13% last quarter, up 2.1 points from the same quarter a year ago.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH still generates free cash flow, though less than at its 2025 peak: $269M over the past year.
LRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$124.8M | +$71.3M |
| Q2 2026 | $316.9M | +6.4% |
| Q1 2026 | $220.4M | +316% |
| Q4 2025 | $92.1M | -59% |
| Q3 2025 | -$196.1M | -$53.4M |
| Q2 2025 | $297.9M | +74% |
| Q1 2025 | $52.9M | -23% |
| Q4 2024 | $222.9M | +29% |
LRN has the edge over CELH on cash flow, with more consistent year-over-year improvement.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has 255M diluted shares, down 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
LRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -5.3% | -2.5M shares |
| 1 year | -8.9% | -4.4M shares |
| 3 years | +4.3% | +1.8M shares |
| 5 years | +11% | +4.3M shares |
| Available history | +12% | +4.9M shares |
LRN has the edge over CELH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $100M |
| Q1 2026 | — |
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has more cash than debt.
LRN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.6x | Net Cash |
| Q1 2026 | -0.4x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -0.8x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
LRN has the edge over CELH on leverage, with a lower net debt burden relative to earnings.
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
LRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.0 | Neutral |
| Stochastic | 15.7 | Oversold |
LRN's weekly RSI is 39 (neutral) and its Stochastic is 16 (oversold).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
LRN PE vs Consumer Defensive Sector
| Metric | LRN | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 19x | 46% below |
| PE % | 3 | 18 | 15 pts below |
LRN has the edge over CELH on valuation relative to its sector.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has the edge over LRN on trend strength, trading above more of its moving averages.
LRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $79.2 | 4.9% below |
| 20 week MA | $82.6 | 8.8% below |
| 50 week MA | $83.0 | 9.3% below |
| 100 week MA | $107.2 | 30% below |
| 200 week MA | $83.2 | 9.5% below |
LRN is in a downtrend: it's below all five of its weekly moving averages, and 9.5% below its 200-week average.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.
LRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.9 | $22.3 | +12% |
| 2021 | $22.3 | $33.6 | +51% |
| 2022 | $33.6 | $32.3 | -4.1% |
| 2023 | $32.3 | $59.4 | +84% |
| 2024 | $59.4 | $105.0 | +77% |
| 2025 | $105.0 | $66.2 | -37% |
| 2026 YTD | $66.2 | $75.3 | +14% |
LRN has the edge over CELH on returns for 2026, with the stronger performance.